Interleukin 2 and the Treatment of Leukemia and Lymphoma

References

• Lotzova E., Savary C. A., Herberman R. B. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J. Immunol 1987; 138: 2718
   PubMed Web of Science ®Google Scholar
• Kasahara T., Hooks J. J., Dougherty S. F., Oppenheim J. J. Interleukin 2 mediated immune interferon (IFN-gamma) production by human T cell and T cell subsets. J. Immunol 1983; 130: 1784
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Gottlieb D. J., Bianchi A. C. M., Meager A., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374
   PubMed Web of Science ®Google Scholar
• Gottleib D. J., Brenner M. K., Heslop H. E., Bello-Fernandez C., Galazka A., Prentice H. G. Effects of recombinant interleukin 2 administration on cytotoxic function following high dose chemoradiotherapy for haematologic malignancy. Blood 1989; 74: 2337
   Google Scholar
• Broxmeyer H. E., Williams D. E., Lu L., Cooper S., Anderson S. L., Beyer G. S., Hoffman R., Rubin Y. Y. The suppressive influences of human tumor necrosis factor on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumour necrosis factor and interferon-gamma. J. Immunol 1986; 136: 4487
   PubMed Web of Science ®Google Scholar
• Price G., Brenner M. K., Prentice H. G., Hoffbrand A. V., Newland A. C. Cytotoxic effects of tumour necrosis factor and gamma interferon on acute myeloid leukaemia blast cells. Br. J. Cancer 1987; 55: 287
   PubMed Web of Science ®Google Scholar
• Murphy M., Loudon R., Kobayashi M., Trinchieri G. y interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte/monocyte colony formation. J. Exp. Med 1986; 164: 263–279
   PubMed Web of Science ®Google Scholar
• Peetre G., Gullberg U., Nilsson E., Olsson I. Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro. J. Clin. Invest 1986; 78: 1694–1700
   PubMed Web of Science ®Google Scholar
• Murase T., Hotta T., Saito H., Ohno R. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 1987; 69: 467–472
   PubMed Web of Science ®Google Scholar
• Munker R., Koeffler P. In vitro action of tumor necrosis factor of myeloid leukemia cells. Blood 1987; 69: 1102–1108
   PubMed Web of Science ®Google Scholar
• Oblakowski P., Bello-Fernandez C. M., Reittie J. R., Heslop H. E., Galatowicz G., Veys P., Wilkes S., Prentice H. G., Hazelhurst G., Hoffbrand A. V., Brenner M. K. Possible mechanism of selective killing of myeloid leukemia blasts by lymphokine-activated killer cells. Blood 1991; 77: 1996
   PubMed Web of Science ®Google Scholar
• Selvaraj P. M., Plunkett M. L., Dustin M. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987; 326: 400–403
   PubMed Web of Science ®Google Scholar
• Davignon D., Martz E., Reynolds T., Kurzinger K., Springer T. A. Lymphocyte function-associated antigen 1 (LFA-1): A surface antigen distinct from Lyt-2,3 that participates in T lymphocyte-mediated killing. Proc. Natl. Acad. Sci. USA 1981; 78: 4535–4539
   PubMed Web of Science ®Google Scholar
• Martin S. D., Springer T. A. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987; 51: 813–819
   PubMed Web of Science ®Google Scholar
• Staunton D. E., Dustin M. L., Springer T. A. Functional cloning of ICAM-2 a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989; 339: 61–64
   PubMed Web of Science ®Google Scholar
• Zinkernagel R. M., Doherty P. C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974; 251: 547–548
   PubMed Web of Science ®Google Scholar
• Imamura N., Kuramoto A. Natural Killer cell activity is not dependent on the CD3Ti T cell receptor antigen complex. Blood 1988; 72: 1837
   PubMed Web of Science ®Google Scholar
• Fisch P., Malkovsky M., Kovats S., Sturm E., Braakamn E., Klein S. B., Voss S. D., Morrisey L. W., DeMars R., Welch W. J., Bolhuis R. L. H., Sondel P. M. Recognition by human Vγ9/Vδ2T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 1990; 250: 1269–1272
   PubMed Web of Science ®Google Scholar
• Foa R., Caretto P., Fierro M. T. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukemia cells of myeloid and lymphoid origin. Br. J. Haematol 1990a; 75: 34–40
   PubMed Web of Science ®Google Scholar
• Armitage R. J., Lai A. P., Roberts P. J., Cawley J. C. Certain myeloid cells possess receptors for interleukin-2. Br. J. Haematol 1986; 64: 799–807
   PubMed Web of Science ®Google Scholar
• Macdonald D., Jiang Y. Z., Swirsky D., Vulliamy T., Morilla R., Bungey J., Barrett A. J. Acute Myeloid leukemia relapsing following interleukin 2 treatment expresses the alpha chain of the interleukin 2 receptor. Brit. J. Hematol 1991; 77: 43–49
   PubMed Web of Science ®Google Scholar
• Rosolen A., Nakanishi M., Poplack D. G. Expression of Interleukin-2 receptor β subunit in hematopoietic malignancies. Blood 1989; 73: 1968–1972
   PubMed Web of Science ®Google Scholar
• Carron J. A., Cawley J. C. IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukemia. Br. J. Haematol 1989; 73: 168–172
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Mule J. J. New approaches to the immunotherapy of cancer using Interleukin-2. Ann. Intern. Med 1988; 108: 853–864
   PubMed Web of Science ®Google Scholar
• Smith K. A. Interleukin-2: Inception, impact and implications. Science 1988; 240: 1169–1176
   PubMed Web of Science ®Google Scholar
• Malkovsky M., Brenner M. K., Hunt R., Rastan S., Dore C., Brown S., North M. E., Asherson G. L., Prentice H. G., Medawar P. T-cell depletion prevents potentiation of graft versus host disease by IL-2. Cell Immunol 1986; 103: 476
   PubMed Web of Science ®Google Scholar
• Sykes M., Romick M. L., Hoyles K. A., Sachs D. H. In vivo administration of Interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J. Exp. Med 1990a; 171: 645–658
   PubMed Web of Science ®Google Scholar
• Sykes M., Romick M. L., Sachs D. H. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci. USA 1990b; 87: 5633–5637
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Brenner M. K., Heslop H. E. A phase I clinical trial of recombinant Interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: Applicability to the elimination of minimal residual disease. Br. J. Cancer 1989a; 60: 610–615
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Duncombe A. S., Reittie J. E., Bello-Fernandez C., Gottlieb D. J., Prentice H. G., Hoffbrand A. V., Brenner M. K. Interleukin 2 infusion induces hemopoietic growth factors and modifies marrow recovery after chemotherapy or autologous bone marrow transplantation. Br. J. Haematol 1991; 77: 237–244
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Stoppa A. M., Viens P., Pourreau C., Lopez M, Attal M., Jasmin C., Monges G., Mawas C. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76(6)1092–1097
   PubMed Web of Science ®Google Scholar
• Foa R., Meloni G., Tosti S. Treatment of residual disease in acute leukemia patients with recombinant Interleukin 2 (IL-2): Clinical and biological findings. Bone Marrow Transplant 1990b; 6: 98–102, (Suppl 1)
   PubMed Web of Science ®Google Scholar
• Reizenstein P. Adjuvant immunotherapy with BCG of acute myeloid leukemia: A 15 year follow up. Brit. J. Haematol 1990; 75: 288–299
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Flournoy N., Sanders J. E. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann. Intern. Med 1987; 107: 809–815
   PubMed Web of Science ®Google Scholar
• Bello-Fernandez C., Bird C., Gottlieb D. J., Heslop H. E., Reittie J. E., Holland M., Prentice H. G., Brenner M. K. The in vivo homeostatic action of IL4 on endogenous and rIL-2 induced activated killer cell function 1991. Blood 1991; 77: 1283
   PubMed Web of Science ®Google Scholar
• Bengtsson M., Simonsson B., Smedmyr B. Immunostimulation post autologous bone marrow transplantation (ABMT) with the novel drug Linomide: Augmentation of T- and NK-cell functions Fifth Internat Symp Autolog Bone Marrow Transplant. Omaha, Nebraska 1990; 113: 234
   Google Scholar